Analysis of prostate cancer risk and aggressiveness via selected SNPs and testing potential for AKR1C3 selective inhibitors as treatment options for prostate cancer

Files in this item

Find Full text

This item appears in the following Collection(s)

Share

Search ResearchSpace


Browse

Statistics